Lp(a) Lowering by Alirocumab Reduces the Total Burden of Cardiovascular Events: ODYSSEY OUTCOMES

This post-hoc analysis of ODYSSEY OUTCOMES evaluated whether alirocumab’s Lp(a)-lowering effect contributed independently to cardiovascular event reduction, beyond what could be explained by LDL-C lowering alone, in 18,924 post-ACS patients.

Alirocumab lowered Lp(a) by approximately 23% from baseline. Using counterfactual modeling to isolate the Lp(a)-lowering effect from simultaneous LDL-C reduction, the investigators found that a substantial fraction of the trial’s cardiovascular benefit was attributable to Lp(a) lowering — independent of LDL-C reduction. The total cardiovascular event burden (including recurrent events, not just first events) was further reduced when Lp(a) lowering was accounted for in analyses, suggesting that Lp(a) contributes to recurrent event risk beyond what LDL-C captures.

ODYSSEY OUTCOMES was not designed as an Lp(a)-lowering trial, and alirocumab’s Lp(a) reduction (~23%) is modest compared with the 70–90% reductions achievable with dedicated Lp(a)-lowering antisense oligonucleotides (pelacarsen) or small interfering RNA (olpasiran, zilebesiran) currently under investigation in cardiovascular outcome trials (HORIZON, OCEAN(a)-Outcomes).

This analysis provides the best available randomized-trial evidence for Lp(a) lowering as an independent therapeutic target — acknowledging that definitive evidence awaits dedicated outcome trials with agents that lower Lp(a) profoundly rather than incidentally.

We rate the evidence strong. A large RCT post-hoc analysis demonstrating that alirocumab’s Lp(a)-lowering effect contributes independently to cardiovascular event reduction — the most rigorous available evidence for Lp(a) as a causal and modifiable cardiovascular risk target, pending dedicated outcome trials.